MDA 2022 infographic: Throughout the disease continuum: Corticosteroid treatment in Duchenne muscular dystrophy
View the key takeaways from our MDA 2022 Virtual Industry Forum, which summarizes the role of corticosteroids in the treatment of patients with Duchenne muscular dystrophy (DMD)
Understand the role of corticosteroids in delaying markers of disease progression in children with DMD
Review the clinical trial data and real-world evidence supporting the use of corticosteroids across multiple stages of disease progression
This is a summary of the Virtual Industry Forum hosted by PTC Therapeutics at the 2022 MDA Annual Clinical & Scientific Conference and was organized and funded by PTC Therapeutics.
Deflazacort is a corticosteroid indicated for the treatment of DMD in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.
For medical information, product complaints, or to report an adverse event, please call 1-866-562-4620 or email at firstname.lastname@example.org. You may also report adverse events directly to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2200062 I March 2022
Sign in or register to access exclusive content on this site